24/7 Market News Snapshot 09 July, 2025 – Iovance Biotherapeutics, Inc. Common Stock (NASDAQ:IOVA)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NASDAQ:IOVA) are discussed in this article.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has recently captured investor attention with a notable increase in stock price, opening at $1.82 and climbing to $1.985, reflecting a rise of 12.15%. This uptick follows a previous close of $1.77, with current trading volumes at 18.74 million shares, indicating robust trading activity. Such substantial price movement may signal a potential breakout, although investors are advised to stay vigilant regarding momentum and resistance levels. Positive technical indicators, including moving averages and volume spikes, suggest an optimistic outlook, though caution is warranted given the possibility of future volatility.

In a related development, Faruqi & Faruqi, LLP, a well-regarded national securities law firm, is conducting an investigation into potential legal claims on behalf of investors in Iovance. This inquiry focuses on individuals who purchased or acquired Iovance securities during the period from August 8, 2024, to May 8, 2025. The firm invites affected investors to discuss their legal rights and options.

Compounding the situation, a federal securities class action has emerged against Iovance, raising serious concerns about the company’s financial disclosures and growth trajectory. Allegations assert that Iovance and its executives misled investors by not adequately revealing critical information regarding the demand for its treatments and the operational efficiency of its treatment centers.

On July 25, 2024, Iovance announced disappointing financial results for the second quarter of fiscal 2024 and drastically lowered its revenue guidance for the year, citing production capacity issues and underwhelming product sales. This led to a severe stock decline of nearly 45% in just one day, marking a drop from $3.17 per share to $1.75.

Faruqi & Faruqi reminds potential class members of the deadline on July 14, 2025, to apply for the role of lead plaintiff in the ongoing litigation. This position involves representing the investor group and is contingent on demonstrating the largest financial stake in the action. Investors with pertinent information about Iovance’s operations are encouraged to engage with the firm regarding their legal rights and the class action process.

Related news for (IOVA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.